Adial Pharmaceuticals, Inc. (ADIL)
NASDAQ: ADIL · Real-Time Price · USD
0.6560
+0.0218 (3.44%)
At close: Apr 1, 2025, 4:00 PM
0.6418
-0.0142 (-2.16%)
After-hours: Apr 1, 2025, 4:35 PM EDT
Company Description
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders.
The company’s lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder.
It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders.
The company was founded in 2010 and is based in Glen Allen, Virginia.
Adial Pharmaceuticals, Inc.
Country | United States |
Founded | 2010 |
IPO Date | Jul 30, 2018 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 5 |
CEO | Cary Claiborne |
Contact Details
Address: 4870 Sadler Road, Suite 300 Glen Allen, Virginia 23060 United States | |
Phone | 804 487 8196 |
Website | adial.com |
Stock Details
Ticker Symbol | ADIL |
Exchange | NASDAQ |
Stock Type | Common Stock |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001513525 |
CUSIP Number | 00688A106 |
ISIN Number | US00688A2050 |
Employer ID | 80-0667150 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Cary John Claiborne MBA | Chief Executive Officer, President and Director |
Tony Goodman | Chief Operating Officer and Director |
Joseph A. M. Truluck M.B.A., MBA | Consultant |
Vinay Shah A.C.A., M.B.A. | Chief Financial Officer and Treasurer |
John R. Martin J.D. | Chief Legal Officer |
Andrew Taubman | Vice President of Corporate Development |
Dr. Brigette Robertson M.D. | Acting Chief Medical Officer |
Abel Svitavsky CPA | Controller |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 21, 2025 | 8-K | Current Report |
Mar 7, 2025 | 8-K | Current Report |
Mar 4, 2025 | 8-K | Current Report |
Mar 4, 2025 | 10-K | Annual Report |
Feb 25, 2025 | 8-K | Current Report |
Jan 13, 2025 | 8-K | Current Report |
Jan 8, 2025 | 8-K | Current Report |
Dec 31, 2024 | 424B3 | Prospectus |
Dec 30, 2024 | EFFECT | Notice of Effectiveness |
Dec 26, 2024 | UPLOAD | Filing |